Literature DB >> 10822447

Increased CSF levels of nerve growth factor in patients with Alzheimer's disease.

C Hock1, K Heese, F Müller-Spahn, P Huber, W Riesen, R M Nitsch, U Otten.   

Abstract

The authors quantitated CSF levels of nerve growth factor (NGF) in patients with AD, nondemented control subjects (CTR), and age-matched patients with major depression (DE). CSF levels of NGF were markedly higher in the AD group than in both the CTR and DE groups (p < 0.01 and p < 0.001). Increased CSF levels of NGF in AD patients may reflect reported accumulation of NGF in the AD brain and may constitute a candidate marker for clinical diagnosis and therapeutic monitoring.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10822447     DOI: 10.1212/wnl.54.10.2009

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

1.  α-Synuclein Aggregates with β-Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects.

Authors:  Simona Daniele; Deborah Pietrobono; Jonathan Fusi; Caterina Iofrida; Lucia Chico; Lucia Petrozzi; Annalisa Lo Gerfo; Filippo Baldacci; Fabio Galetta; Gabriele Siciliano; Ubaldo Bonuccelli; Gino Santoro; Maria Letizia Trincavelli; Ferdinando Franzoni; Claudia Martini
Journal:  Mol Neurobiol       Date:  2017-04-18       Impact factor: 5.590

Review 2.  Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations.

Authors:  R G Thorne; W H Frey
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Serum growth factors and neuroprotective surveillance: focus on IGF-1.

Authors:  I Torres-Aleman
Journal:  Mol Neurobiol       Date:  2000-06       Impact factor: 5.590

4.  Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay.

Authors:  Yuan Yuan Hu; Shan Shu He; Xiaochuan Wang; Qiu Hong Duan; Inge Grundke-Iqbal; Khalid Iqbal; Jianzhi Wang
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

5.  Increased matrix metalloproteinase 9 activity in mild cognitive impairment.

Authors:  Martin A Bruno; Elliott J Mufson; Joanne Wuu; A Claudio Cuello
Journal:  J Neuropathol Exp Neurol       Date:  2009-12       Impact factor: 3.685

6.  Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer's Disease.

Authors:  Scott E Counts; Bin He; John G Prout; Bernadeta Michalski; Lucia Farotti; Margaret Fahnestock; Elliott J Mufson
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

Review 7.  Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease?

Authors:  Christian Humpel
Journal:  Exp Gerontol       Date:  2010-11-26       Impact factor: 4.032

Review 8.  Identifying and validating biomarkers for Alzheimer's disease.

Authors:  Christian Humpel
Journal:  Trends Biotechnol       Date:  2010-10-23       Impact factor: 19.536

Review 9.  Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Curr Alzheimer Res       Date:  2012-01       Impact factor: 3.498

Review 10.  A review: inflammatory process in Alzheimer's disease, role of cytokines.

Authors:  Jose Miguel Rubio-Perez; Juana Maria Morillas-Ruiz
Journal:  ScientificWorldJournal       Date:  2012-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.